InvestorsHub Logo
Followers 10
Posts 212
Boards Moderated 0
Alias Born 04/26/2017

Re: alx8967 post# 481

Thursday, 08/10/2017 9:27:49 AM

Thursday, August 10, 2017 9:27:49 AM

Post# of 1954
I think (if my math is not too far off), results should be expected around oct 16-nov 6 range, based on time from last patient dosed, giving them 2-4 weeks to clean up data, as they stated would be needed during conference call. Agreed that we have come too far to turn back now lol.

It's notoriously difficult to find Nash type patients for trials, getting the FDA to expand the criteria was a strong move. Also shows the FDA is willing to work with them in a reasonable fashion. Some companies have to request dedicated meetings and jump through millions of hoops to get that type of exception approved. They obviously filled out the request form appropriately and with a reasonable counter claim for new criteria. They are getting things done. It's only a startup biotech... I am honestly impressed with how well they are handling things, given their size and the age of the company. Whenever things happen too quickly in the biotech world, bad things follow. They have been transparent and thorough, from what I can tell, all just my opinion. A rarity. Most startups are dumping shares and making promises right about now in the world of Wall Street biotech. Happy Thursday... countdown continues!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VKTX News